The US Biosecure Act - JPT is not affected!
Published on 10/09/2024
Navigating the U.S. BIOSECURE Act
The U.S. BIOSECURE Act is a legislative proposal focused on enhancing national security by restricting biotech companies with ties to foreign adversaries, primarily China. While this may drastically impact companies working within or with U.S. federal agencies, not all biotechnology firms are affected.
What Does the BIOSECURE Act Do?
The Act is designed to protect American intellectual property and genetic data from foreign exploitation. It imposes strict prohibitions on contracting, procurement, and funding for companies deemed a "biotechnology company of concern." Primarily targeting Chinese firms, it will affect the entire U.S. biotech industry by reshaping supply chains and raising compliance costs.
Impact on Peptide Synthesis & JPT
Peptide synthesis is crucial in drug development and research. The BIOSECURE Act may disrupt the peptide supply chain, as many materials and services currently come from China. However, European companies like JPT Peptide Technologies, based and producing only in Germany, remain unaffected. JPT's peptide synthesis services offer a secure, compliant alternative for U.S. companies.
What’s Next?
While the Act is still progressing through Congress, its passage could reshape global biotech dynamics, creating new opportunities for non-Chinese firms. Companies like JPT are well positioned to fill the gap and ensure uninterrupted service to U.S. partners.
Visit our webpage for more information on the Biosecure Act, JPT’s peptide synthesis offers and our quality measures and assurance.